X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MVR-T3011, ImmVira's proprietary, 3-in-1 oHSV, is a novel genetic engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells. It is being evaluated for Head and neck squamous cell carcinomas.
Lead Product(s): MVR-T3011
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2024
Details:
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetically engineered oHSV, which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells.
Lead Product(s): MVR-T3011
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
MVR-C5252 designed to treat CNS tumors, has shown precisely attenuated to achieve on-target malignant gliocyte killing while maintaining safety profile and it also carries specific therapeutic exogenous genes to promote the immune response of tumor microenvironment for further anti-tumor activity.
Lead Product(s): C5252
Therapeutic Area: Oncology Product Name: MVR-C5252
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells.
Lead Product(s): MVR-T3011,Pembrolizumab
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
The funds raised from financing will be mainly used to support the clinical trials of MVR-T3011, mono and combo therapies of three pipelines under clinical stage in both U.S. and China, the subsequent IND applications of oncolytic virus and exosome product pipelines.
Lead Product(s): T3011,Pembrolizumab
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: China Merchants China Direct Investments
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing October 26, 2022
Details:
Developed on ImmVira's OvPENS new drug development platform, MVR-C5252 is designed specifically for the treatment of glioma by specific attenuation to achieve on-target malignant gliocyte killing while maintaining safety profile.
Lead Product(s): C5252
Therapeutic Area: Oncology Product Name: MVR-C5252
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2022
Details:
MVR-T3011 (T3011) IV is ImmVira's proprietary 3-in-1 oHSV with novel virus backbone modification strategy, allowing the great breakthrough in intravenous administration to treat metastatic tumors.
Lead Product(s): T3011,Pembrolizumab
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells.
Lead Product(s): MVR-T3011,Cobimetinib
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 19, 2022
Details:
Preliminary data from MVR-T3011 IV, an oncolytic herpes simplex virus with novel virus backbone modification strategy, Phase I clinical study has demonstrated robust safety results to treat metastatic tumors.
Lead Product(s): MVR-T3011
Therapeutic Area: Oncology Product Name: MVR-T3011
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
MVR-T3011, ImmVira's proprietary next-generation, genetically modified oncolytic herpes simplex virus ("oHSV"), is developed on a novel virus backbone design driven by ImmVira's innovative insights in oncolytic viruses and superior gene recombinant technology.
Lead Product(s): T3011
Therapeutic Area: Oncology Product Name: T3011
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
